Welcome to our dedicated page for Claritev SEC filings (Ticker: MPLNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Claritev's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Claritev's regulatory disclosures and financial reporting.
Claritev Corp senior vice president and chief strategy officer William B. Mintz reported equity compensation activity tied to restricted stock units. On March 1, 2026, he disposed of 6,431 cash-settled RSUs back to the company upon vesting of half of a 2025 cRSU grant, leaving 6,432 cash-settled RSUs outstanding. On the same date, 1,137 Class A common shares at $13.47 per share were withheld to cover taxes on vesting of earlier RSUs. He also received a new grant of 19,060 restricted stock units, scheduled to vest in four equal annual installments of 25% each on March 1, 2027, 2028, 2029, and 2030. Following these transactions, Mintz directly held 83,248 shares of Class A common stock.
Claritev Corp reported that SVP and Chief Accounting Officer Albinson Brock acquired an equity award tied to 23,243 shares of Class A common stock as a grant of restricted stock units. These RSUs vest 25% each on March 1 of 2027, 2028, 2029 and 2030. Following this grant, Brock beneficially owns 27,237 shares directly.
Claritev Corp SVP and Chief Growth Officer Tiffani Misencik reported a mix of equity award activity and related share dispositions. She received a grant of 26,342 restricted stock units, which will vest 25% each year on March 1 of 2027, 2028, 2029, and 2030.
On the same date, 10,123 cash-settled restricted stock units granted in 2025 were settled in cash following the vesting of 50% of that award. In addition, 1,660 shares of Class A common stock at $13.47 per share were withheld to cover taxes on vesting, leaving her with 132,573 Class A shares directly owned.
Claritev Corp executive Carol Nutter, SVP and Chief People Officer, reported multiple equity transactions. She received a grant of 18,130 shares of Class A common stock as restricted stock units, which will vest 25% each on March 1 of 2027, 2028, 2029 and 2030.
On the same date, Nutter disposed of 1,229, 498 and 1,085 Class A shares at $13.47 per share to cover taxes on vesting RSUs originally granted in 2023, 2024 and 2025. She also disposed of 6,127 cash-settled restricted stock units through a cash settlement tied to 50% vesting of a prior cRSU grant. After these transactions, she directly owns 46,066 Class A shares.
Claritev Corp director and CEO Dalton Travis reported a mix of equity award activity and related share disposals on March 1, 2026. He received a grant of 278,925 shares of Class A common stock as a restricted stock unit award, recorded as a grant or other acquisition. To cover tax obligations from vesting of earlier restricted stock units granted on March 1, 2024 and March 1, 2025, 13,806 and 9,824 Class A shares, respectively, were disposed of through tax-withholding transactions at a price of $13.47 per share. In addition, 190,566 cash settled restricted stock units granted on March 1, 2025 were settled in cash upon vesting of 50% of those units, reducing his position in that derivative security. After these transactions, he directly held 498,353 Class A shares and 190,567 cash settled restricted stock units, and there were 24,952 Class A shares held indirectly through his spouse’s individual retirement account.
Claritev Corp executive vice president and chief digital officer Kim Michael reported an open-market purchase of 30,000 shares of Class A common stock on February 27, 2026 at a weighted average price of $14.2985 per share. Following this transaction, Michael directly owns 137,973 shares.
Claritev Corp director and Pres., CEO & Executive Chair Dalton Travis reported an open-market purchase of 15,380 shares of Class A common stock on February 27, 2026. The shares were bought indirectly through his spouse's individual retirement account at a weighted average price of $12.9992 per share. After these transactions, he reported 24,952 shares held indirectly through the spouse’s IRA and 243,058 shares held directly.
Claritev Corp senior vice president and general counsel Tara O'Neil reported an open-market purchase of 750 shares of Class A common stock at a price of $12.99 per share. Following this transaction, her directly held stake increased to 27,199 shares.
Claritev Corporation describes itself as a technology, data and insights company focused on reducing cost, risk and complexity in the U.S. healthcare system. The company serves more than 750 payer clients and estimates its solutions touch over 60 million consumers through 100,000+ plan sponsors.
Claritev reports identifying $25.0 billion in potential savings on $179.8 billion in claim charges in 2025, leveraging a platform that processes about 30 million claims per month and a proprietary network of over 1.4 million contracted providers. It estimates total addressable markets of roughly $10.0 billion for out-of-network cost management, $3.0 billion for in‑network payment and revenue integrity, and $17.0 billion for newer analytics and transparency offerings.
The report outlines the Vision 2030 strategy and notes 2025 was branded “THE TURN,” marking a return to year‑over‑year revenue growth, with 2026 branded “THE WAY UP.” Key risks include dependence on a few large clients, high leverage, intense competition, extensive healthcare regulation and cybersecurity and data‑privacy exposure. As of June 30 2025, non‑affiliate market value was about $505.8 million, and as of February 23 2026, 16,552,723 Class A shares were outstanding.
Claritev Corporation reported Q4 2025 revenue of $246.6 million, up 6.2% from Q4 2024, and narrowed its quarterly net loss to $80.6 million. Adjusted EBITDA for Q4 was $151.3 million with a 61.4% margin, and free cash flow improved to $36.4 million.
For full-year 2025, revenue reached $965.4 million, a 3.7% increase, while the net loss shrank sharply to $284.3 million from $1.65 billion. Full-year Adjusted EBITDA rose to $602.6 million, and operating cash flow was $117.3 million.
The company issued 2026 guidance with revenue between $980 million and $1 billion, Adjusted EBITDA of $605 million to $615 million, capital expenditures of $160 million to $170 million, and free cash flow between $0 million and $10 million. The board also approved a five-year share repurchase program authorizing up to $75 million of Class A common stock, capped at $20 million per year and funded from cash on hand and operations.